Real feedback on the efficacy and safety of the Lao version of generic capmatinib

The Lao version of Capmatinib (Capmatinib) generic drug has attracted the attention of many patients in recent years, especially for non-small cell lung cancer patients with MET exon 14 skipping mutations. Capmatinib is the first highly selective MET inhibitor approved by the FDA. Clinical data shows that it has a higher response rate and longer progression-free survival in patients with relevant mutations. Since the domestic market has not long been launched and the supply of drugs is still gradually expanding, some patients will choose overseas channels to obtain drugs. Among them, the Lao version of generic drugs is favored due to its price advantage.

In terms of efficacy, the Lao version of capmatinib’s generic version maintains highly consistent ingredients and dosages with the original drug. Therefore, most patients report that its clinical effects are not much different from the original drug. Some patients who have tried the Lao version of the generic drug said that the tumor burden was significantly reduced, symptoms such as dyspnea and cough were significantly improved, and the quality of life was improved. Judging from clinical feedback, its actual efficacy can meet the treatment needs of most RET mutation patients, and is especially suitable for patient groups who are price-sensitive or have difficulty obtaining original drugs.

In terms of safety, the side effects of the Lao version of capmatinib are generally consistent with those of the original drug, mainly including peripheral edema, nausea, decreased appetite, fatigue, and mild liver function abnormalities. Most patients stated that these adverse reactions could be controlled through dose adjustment or symptomatic treatment, and did not significantly affect long-term medication adherence. Compared with some multi-target TKIs, capmatinib is generally well tolerated, so its safety profile remains acceptable even in generic versions.

In terms of price, capmatinib has been successfully launched in China and has been included in medical insurance, but it is still difficult to purchase it in pharmacies in some areas. The price of original drugs in overseas markets is generally high, mostly around tens of thousands of yuan, while the price of Laotian generic drugs is much more affordable, costing only more than 2,000 yuan. For patients on long-term treatment, such a cost gap is very considerable, making the Lao version of capmatinib a realistic choice for many patients to relieve financial pressure. Overall, the Lao version of generic drugs not only ensures efficacy and safety, but also improves drug accessibility.

Reference link:https://www.drugs.com